BRUSSELS, BELGIUM & SAN FRANCISCO, USA – April 20, 2026 – Global biopharmaceutical leader UCB has finalized a definitive agreement…
Read More
The Non-GLP-1 Obesity Drug Market Set for Explosive 50-Fold Growth, Reaching $15.5 Billion by 2031
The global pharmaceutical market for obesity treatments is poised for a dramatic transformation, with a burgeoning segment of non-Glucagon-like peptide-1…
Read More
Boehringer Ingelheim Establishes Cutting-Edge AI and Machine Learning Hub in London to Accelerate Targeted Medicine Discovery
Boehringer Ingelheim has officially launched a new, state-of-the-art Artificial Intelligence (AI) and Machine Learning (ML) center in London’s King’s Cross,…
Read More
US President Signs Executive Order to Expedite Psychedelic Drug Review and Bolster Research
In a significant move poised to reshape the landscape of mental health treatment, U.S. President Donald Trump has signed an…
Read More
Boehringer Ingelheim and Zai Lab Forge Clinical Collaboration to Pioneer Novel Combination Therapy for Aggressive Lung Cancers
Boehringer Ingelheim and Zai Lab have announced a significant clinical collaboration aimed at investigating a dual delta-like ligand 3 (DLL3)-targeting…
Read More
Cochrane Review Challenges Clinical Significance of Anti-Amyloid Alzheimer’s Drugs, Pharmaceutical Companies Reaffirm Efficacy
A comprehensive review of 17 clinical trials by the esteemed Cochrane organization has cast doubt on the clinically meaningful benefits…
Read More
Daiichi Sankyo Partners with Interna Therapeutics to Revolutionize Targeted Drug Delivery with Molecular Nano Motor Technology
Boston, MA & Tokyo, Japan – April 17, 2026 – In a significant move to enhance the precision and efficacy…
Read More
The Dawn of In Vivo Cell Therapies: A New Era in Precision Medicine Unfolds Amidst Significant Investment and Innovation
The pharmaceutical landscape is witnessing a profound transformation with the ascendance of in vivo cell therapies, a revolutionary approach that…
Read More
Aligos Therapeutics Licenses Pevifoscorvir Sodium to Xiamen Amoytop Biotech for Greater China, Bolstering HBV Treatment Landscape
Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech, granting the Chinese biopharmaceutical company the rights…
Read More
Kailera Therapeutics Secures $625 Million in Landmark IPO to Accelerate Obesity Drug Development
Obesity-focused biotechnology firm Kailera Therapeutics has successfully launched its Initial Public Offering (IPO), raising an impressive $625 million. This significant…
Read More
